US-based Biogen Idec plans to roll out its entire range of medicines in the fast-growing, Rs 40,000-crore Indian retail drug market over the next few years through its wholly-owned Indian arm.
The company has also not renewed its product distribution agreement with Piramal Healthcare which expired last December, a top company official said. “Our five-year marketing tie-up with Piramal Healthcare for Avonex expired last year-end. The drug is now being sold by our own sales team,” said Biogen Idec Biotech India managing director Alpna Seth.
Biogen Idec, one of the largest biotech drugmakers globally, had set up its wholly-owned Indian subsidiary in 2007, but the firm was not engaged in commercial activity.
